Novateur Ventures explores new strategy to reduce hyperinflammatory response caused by COVID-19

August 12, 2020

A novel strategy has been developed by Frontiers in Pharmacology, a leading peer-reviewed journal.

The strategy co-authored by Ali Ardakani, Founder & Managing Director at Novateur Ventures, and Dr. Colin D. Funk (Queen's University, Kingston) analyzes lipid mediators, known as leukotrienes, as the cause for hyperinflammatory response manifested in severe COVID-19 cases. Patients with severe COVID-19 develop an overwhelming state of inflammation with multi-organ dysfunction and leukotrienes have been overlooked.

"Globally the race to develop new therapeutics or repurpose existing drugs to cultivate an effective therapeutic treatment for COVID- 19 is urgent. At Novateur, our research has been well underway since the first cases were discovered," says Ardakani. "I am very pleased today to announce a strategy we believe can potentially impact COVID-19 patients in a safe and effective manner."

Since Novateur began their in-depth studies, only two treatments (remdesivir, dexamethasone) have demonstrated modest ability to reduce disease progression and severity; however, there is still a high unmet need for additional improvement. Leukotrienes have some of the most potent impacts on immune cell trafficking and vascular leakage in biological systems, two important steps that take place in COVID-19. Novateur's research proposes a simple treatment paradigm using two generic drugs, normally directed to blocking inflammation in airways of patients with asthma, to target the hyper-inflammatory response insevere COVID-19.This will be accomplished by a combination of a leukotriene biosynthesis blocker zileuton (Zyflo® controlled release formulation) and an inhibitor of the cysteinyl leukotriene 1 receptor montelukast (Singulair®). Both these agents, now generic, have been on the market for many years, and their activity and side effects in humans are well known.

In COVID-19, providing zileuton/montelukast combination prior to out-of-control host inflammatory cell recruitment to the lungs and before pulmonary edema sets in is paramount. Initiation of treatment with zileuton/montelukast should take place early on, shortly after a positive test is confirmed and before major symptoms arise. Currently it remains very difficult to predict which patients will progress to severe COVID-19 disease. The standard of care is basically symptomatic control (i.e. acetaminophen for fever and muscle pain) and observation. The proposed zileuton/montelukast combination could readily be added in this setting, with the goal to switch off the hyper-inflammatory response. The incentive to move forward quickly is vital to combat COVID-19 while waiting for a preventative vaccine or other treatments.

"Our journey studying COVID-19 and potential therapeutics is still at an early stage. We hope that our proposed treatment plan can effectively stop COVID-19 from becoming a life-threatening disorder," says Funk, a key leader in the leukotriene field. "Novateur will continue to concentrate its efforts on this global pandemic that has claimed the lives of so many. It is important to recognize the sharing of critical data and the very collaborative approach this fight has taken. We are working diligently with unprecedented speed to move a clinical trial forward as quickly as possible in the USA where cases of COVID-19 are high."
About Novateur Ventures

Novateur is an established global life sciences advisory with extensive experience related to business development and product development of therapeutics, medical devices and digital health products. Visit:

Novateur Ventures has also launched '

Kamran Shaikh
PR Associates
(778) 846-5406

A photo accompanying this announcement is available at

PR Associates

Related Strategy Articles from Brightsurf:

Novel antiviral strategy for treatment of COVID-19
A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.

A new strategy of cell entry for some types of parvoviruses
Researchers at the Institut national de la recherche scientifique (INRS), in collaboration with American scientists, have uncovered a new parvovirus strategy for reaching the cell nucleus which is their site of replication.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

Can a quantum strategy help bring down the house?
Now researchers at MIT and Caltech have shown that the weird, quantum effects of entanglement could theoretically give blackjack players even more of an edge, albeit a small one, when playing against the house.

A new strategy to create 2D magnetic order
Scientists based in China discover the spin-valve magnetoresistance at the ferromagnetic SrRuO3 grain boundary owing to the nature of non-magnetic metallic grain boundary revealed by electron microscopy and first principles calculations, providing a new strategy to create the low-dimensional magnetic order via defect engineering.

New nano strategy fights superbugs
Rice University researchers imprint carbon nitride nanosheets to catch and kill free-floating antibiotic resistant genes found in secondary effluent produced by wastewater treatment plants.

A new treatment strategy against MERS
First identified in 2012, the MERS-coronavirus is capable of causing severe pneumonia.

Memory training builds upon strategy use
Researchers from Åbo Akademi University, Finland, and Umeå University, Sweden, have for the first time obtained clear evidence of the important role strategies have in memory training.

New strategy to treat Parkinson's disease
Scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful genetic mutations.

A new strategy for the synthesis of complex natural products
Chemists from the University of Basel have succeeded in synthesizing two complex natural products from the group of dithiodiketopiperazines (DTPs).

Read More: Strategy News and Strategy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to